Household & Personal Products
Compare Stocks
5 / 10Stock Comparison
SKIN vs USNA vs NUS vs AMZN vs ELF
Revenue, margins, valuation, and 5-year total return — side by side.
Packaged Foods
Household & Personal Products
Specialty Retail
Household & Personal Products
SKIN vs USNA vs NUS vs AMZN vs ELF — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Household & Personal Products | Packaged Foods | Household & Personal Products | Specialty Retail | Household & Personal Products |
| Market Cap | $118M | $359M | $345M | $2.92T | $3.44B |
| Revenue (TTM) | $296M | $925M | $1.49B | $742.78B | $1.52B |
| Net Income (TTM) | $-6M | $11M | $160M | $90.80B | $104M |
| Gross Margin | 64.9% | 76.6% | 69.4% | 50.6% | 70.3% |
| Operating Margin | -3.6% | 5.5% | 4.4% | 11.5% | 11.1% |
| Forward P/E | — | 11.2x | 7.0x | 34.8x | 19.9x |
| Total Debt | $379M | $14M | $364M | $152.99B | $313M |
| Cash & Equiv. | $233M | $158M | $239M | $86.81B | $149M |
SKIN vs USNA vs NUS vs AMZN vs ELF — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 20 | May 26 | Return |
|---|---|---|---|
| The Beauty Health C… (SKIN) | 100 | 9.0 | -91.0% |
| USANA Health Scienc… (USNA) | 100 | 25.9 | -74.1% |
| Nu Skin Enterprises… (NUS) | 100 | 13.6 | -86.4% |
| Amazon.com, Inc. (AMZN) | 100 | 171.2 | +71.2% |
| e.l.f. Beauty, Inc. (ELF) | 100 | 284.2 | +184.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SKIN vs USNA vs NUS vs AMZN vs ELF
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, SKIN doesn't own a clear edge in any measured category.
USNA ranks third and is worth considering specifically for sleep-well-at-night and defensive.
- Lower volatility, beta 1.34, Low D/E 2.4%, current ratio 2.24x
- Beta 1.34, current ratio 2.24x
- Beta 1.34 vs ELF's 2.36, lower leverage
NUS is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 0 yrs, beta 1.49, yield 3.4%
- Lower P/E (7.0x vs 34.8x)
- 3.4% yield; the other 4 pay no meaningful dividend
AMZN carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 7.0% 10Y total return vs ELF's 133.1%
- 12.2% margin vs SKIN's -2.0%
- +43.7% vs SKIN's -35.9%
- 11.5% ROA vs SKIN's -1.2%, ROIC 14.7% vs -6.8%
ELF is the clearest fit if your priority is growth exposure and valuation efficiency.
- Rev growth 28.3%, EPS growth -13.1%, 3Y rev CAGR 49.6%
- PEG 0.49 vs AMZN's 1.24
- 28.3% revenue growth vs NUS's -14.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 28.3% revenue growth vs NUS's -14.3% | |
| Value | Lower P/E (7.0x vs 34.8x) | |
| Quality / Margins | 12.2% margin vs SKIN's -2.0% | |
| Stability / Safety | Beta 1.34 vs ELF's 2.36, lower leverage | |
| Dividends | 3.4% yield; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +43.7% vs SKIN's -35.9% | |
| Efficiency (ROA) | 11.5% ROA vs SKIN's -1.2%, ROIC 14.7% vs -6.8% |
SKIN vs USNA vs NUS vs AMZN vs ELF — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SKIN vs USNA vs NUS vs AMZN vs ELF — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
NUS leads in 1 of 6 categories
USNA leads 1 • AMZN leads 1 • ELF leads 1 • SKIN leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — AMZN and ELF each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AMZN is the larger business by revenue, generating $742.8B annually — 2508.2x SKIN's $296M. AMZN is the more profitable business, keeping 12.2% of every revenue dollar as net income compared to SKIN's -2.0%. On growth, ELF holds the edge at +37.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $296M | $925M | $1.5B | $742.8B | $1.5B |
| EBITDAEarnings before interest/tax | $9M | $91M | $118M | $155.9B | $235M |
| Net IncomeAfter-tax profit | -$6M | $11M | $160M | $90.8B | $104M |
| Free Cash FlowCash after capex | $29M | $9M | $46M | -$2.5B | $215M |
| Gross MarginGross profit ÷ Revenue | +64.9% | +76.6% | +69.4% | +50.6% | +70.3% |
| Operating MarginEBIT ÷ Revenue | -3.6% | +5.5% | +4.4% | +11.5% | +11.1% |
| Net MarginNet income ÷ Revenue | -2.0% | +1.2% | +10.8% | +12.2% | +6.8% |
| FCF MarginFCF ÷ Revenue | +9.8% | +0.9% | +3.1% | -0.3% | +14.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -6.7% | +5.9% | -16.9% | +16.6% | +37.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +38.0% | -142.2% | +139.7% | +74.8% | +116.7% |
Valuation Metrics
NUS leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 2.2x trailing earnings, NUS trades at a 94% valuation discount to AMZN's 37.8x P/E. Adjusting for growth (PEG ratio), ELF offers better value at 0.79x vs AMZN's 1.35x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $118M | $359M | $345M | $2.92T | $3.4B |
| Enterprise ValueMkt cap + debt − cash | $264M | $215M | $471M | $2.98T | $3.6B |
| Trailing P/EPrice ÷ TTM EPS | -5.69x | 33.55x | 2.21x | 37.82x | 32.18x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 11.18x | 7.02x | 34.77x | 19.89x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 1.35x | 0.79x |
| EV / EBITDAEnterprise value multiple | 7331.15x | 2.37x | 3.29x | 20.47x | 17.85x |
| Price / SalesMarket cap ÷ Revenue | 0.39x | 0.39x | 0.23x | 4.07x | 2.62x |
| Price / BookPrice ÷ Book value/share | 2.02x | 0.62x | 0.44x | 7.14x | 4.74x |
| Price / FCFMarket cap ÷ FCF | 3.17x | 42.13x | 7.50x | 378.98x | 29.86x |
Profitability & Efficiency
USNA leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
AMZN delivers a 23.3% return on equity — every $100 of shareholder capital generates $23 in annual profit, vs $-9 for SKIN. USNA carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), SKIN scores 7/9 vs AMZN's 6/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -9.4% | +1.8% | +20.4% | +23.3% | +8.9% |
| ROA (TTM)Return on assets | -1.2% | +1.5% | +11.3% | +11.5% | +4.5% |
| ROICReturn on invested capital | -6.8% | +8.6% | +7.3% | +14.7% | +13.5% |
| ROCEReturn on capital employed | -4.5% | +8.3% | +7.9% | +15.3% | +16.6% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 | 6 | 6 | 7 |
| Debt / EquityFinancial leverage | 6.20x | 0.02x | 0.45x | 0.37x | 0.41x |
| Net DebtTotal debt minus cash | $146M | -$144M | $126M | $66.2B | $164M |
| Cash & Equiv.Liquid assets | $233M | $158M | $239M | $86.8B | $149M |
| Total DebtShort + long-term debt | $379M | $14M | $364M | $153.0B | $313M |
| Interest CoverageEBIT ÷ Interest expense | 0.81x | 50.32x | 15.14x | 39.96x | 6.48x |
Total Returns (Dividends Reinvested)
AMZN leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ELF five years ago would be worth $20,505 today (with dividends reinvested), compared to $707 for SKIN. Over the past 12 months, AMZN leads with a +43.7% total return vs SKIN's -35.9%. The 3-year compound annual growth rate (CAGR) favors AMZN at 36.8% vs SKIN's -56.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -35.0% | +0.1% | -26.9% | +19.7% | -20.6% |
| 1-Year ReturnPast 12 months | -35.9% | -31.4% | +26.3% | +43.7% | -7.2% |
| 3-Year ReturnCumulative with dividends | -91.7% | -70.7% | -77.1% | +156.2% | -31.4% |
| 5-Year ReturnCumulative with dividends | -92.9% | -80.0% | -80.0% | +64.8% | +105.0% |
| 10-Year ReturnCumulative with dividends | -91.6% | -68.7% | -48.8% | +697.8% | +133.1% |
| CAGR (3Y)Annualised 3-year return | -56.4% | -33.6% | -38.9% | +36.8% | -11.8% |
Risk & Volatility
Evenly matched — USNA and AMZN each lead in 1 of 2 comparable metrics.
Risk & Volatility
USNA is the less volatile stock with a 1.34 beta — it tends to amplify market swings less than ELF's 2.36 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMZN currently trades 97.3% from its 52-week high vs SKIN's 33.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.00x | 1.34x | 1.49x | 1.51x | 2.36x |
| 52-Week HighHighest price in past year | $2.69 | $38.32 | $14.62 | $278.56 | $150.99 |
| 52-Week LowLowest price in past year | $0.76 | $16.60 | $5.65 | $185.01 | $58.05 |
| % of 52W HighCurrent price vs 52-week peak | +33.8% | +50.8% | +48.0% | +97.3% | +40.9% |
| RSI (14)Momentum oscillator 0–100 | 52.1 | 59.0 | 46.4 | 81.1 | 42.3 |
| Avg Volume (50D)Average daily shares traded | 760K | 118K | 458K | 45.5M | 2.3M |
Analyst Outlook
ELF leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: SKIN as "Hold", USNA as "Hold", NUS as "Hold", AMZN as "Buy", ELF as "Buy". Consensus price targets imply 79.9% upside for USNA (target: $35) vs 13.1% for AMZN (target: $307). NUS is the only dividend payer here at 3.35% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $1.30 | $35.00 | $11.00 | $306.77 | $95.17 |
| # AnalystsCovering analysts | 13 | 8 | 11 | 94 | 27 |
| Dividend YieldAnnual dividend ÷ price | — | — | +3.4% | — | — |
| Dividend StreakConsecutive years of raises | — | — | 0 | — | 1 |
| Dividend / ShareAnnual DPS | — | — | $0.24 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +7.7% | +5.8% | 0.0% | +1.9% |
NUS leads in 1 of 6 categories (Valuation Metrics). USNA leads in 1 (Profitability & Efficiency). 2 tied.
SKIN vs USNA vs NUS vs AMZN vs ELF: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SKIN or USNA or NUS or AMZN or ELF a better buy right now?
For growth investors, e.
l. f. Beauty, Inc. (ELF) is the stronger pick with 28. 3% revenue growth year-over-year, versus -14. 3% for Nu Skin Enterprises, Inc. (NUS). Nu Skin Enterprises, Inc. (NUS) offers the better valuation at 2. 2x trailing P/E (7. 0x forward), making it the more compelling value choice. Analysts rate Amazon. com, Inc. (AMZN) a "Buy" — based on 94 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SKIN or USNA or NUS or AMZN or ELF?
On trailing P/E, Nu Skin Enterprises, Inc.
(NUS) is the cheapest at 2. 2x versus Amazon. com, Inc. at 37. 8x. On forward P/E, Nu Skin Enterprises, Inc. is actually cheaper at 7. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: e. l. f. Beauty, Inc. wins at 0. 49x versus Amazon. com, Inc. 's 1. 24x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — SKIN or USNA or NUS or AMZN or ELF?
Over the past 5 years, e.
l. f. Beauty, Inc. (ELF) delivered a total return of +105. 0%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: AMZN returned +697. 8% versus SKIN's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SKIN or USNA or NUS or AMZN or ELF?
By beta (market sensitivity over 5 years), USANA Health Sciences, Inc.
(USNA) is the lower-risk stock at 1. 34β versus e. l. f. Beauty, Inc. 's 2. 36β — meaning ELF is approximately 75% more volatile than USNA relative to the S&P 500. On balance sheet safety, USANA Health Sciences, Inc. (USNA) carries a lower debt/equity ratio of 2% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.
05Which is growing faster — SKIN or USNA or NUS or AMZN or ELF?
By revenue growth (latest reported year), e.
l. f. Beauty, Inc. (ELF) is pulling ahead at 28. 3% versus -14. 3% for Nu Skin Enterprises, Inc. (NUS). On earnings-per-share growth, the picture is similar: Nu Skin Enterprises, Inc. grew EPS 207. 8% year-over-year, compared to -73. 5% for USANA Health Sciences, Inc.. Over a 3-year CAGR, ELF leads at 49. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SKIN or USNA or NUS or AMZN or ELF?
Amazon.
com, Inc. (AMZN) is the more profitable company, earning 10. 8% net margin versus -3. 2% for The Beauty Health Company — meaning it keeps 10. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ELF leads at 12. 0% versus -6. 9% for SKIN. At the gross margin level — before operating expenses — USNA leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SKIN or USNA or NUS or AMZN or ELF more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, e. l. f. Beauty, Inc. (ELF) is the more undervalued stock at a PEG of 0. 49x versus Amazon. com, Inc. 's 1. 24x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Nu Skin Enterprises, Inc. (NUS) trades at 7. 0x forward P/E versus 34. 8x for Amazon. com, Inc. — 27. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for USNA: 79. 9% to $35. 00.
08Which pays a better dividend — SKIN or USNA or NUS or AMZN or ELF?
In this comparison, NUS (3.
4% yield) pays a dividend. SKIN, USNA, AMZN, ELF do not pay a meaningful dividend and should not be held primarily for income.
09Is SKIN or USNA or NUS or AMZN or ELF better for a retirement portfolio?
For long-horizon retirement investors, Nu Skin Enterprises, Inc.
(NUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (3. 4% yield). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NUS: -48. 8%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SKIN and USNA and NUS and AMZN and ELF?
These companies operate in different sectors (SKIN (Consumer Defensive) and USNA (Consumer Defensive) and NUS (Consumer Defensive) and AMZN (Consumer Cyclical) and ELF (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: SKIN is a small-cap quality compounder stock; USNA is a small-cap quality compounder stock; NUS is a small-cap deep-value stock; AMZN is a mega-cap quality compounder stock; ELF is a small-cap high-growth stock. NUS pays a dividend while SKIN, USNA, AMZN, ELF do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.